Qureight and Avalyn Pharma Announce Partnership in Progressive Pulmonary Fibrosis
Qureight Ltd and Avalyn Pharma Inc. have announced a strategic partnership to advance research in progressive pulmonary fibrosis (PPF), a devastating lung disease with limited treatment options.
This collaboration begins with the MIST study, a Phase 2b clinical trial evaluating the safety and efficacy of Avalyn’s lead investigational therapy, AP01 (inhaled pirfenidone), in PPF patients.
This partnership marks a significant milestone in the field, as it is the first time deep-learning imaging technologies have been integrated into a PPF clinical study. By leveraging Qureight’s advanced imaging platform, the study aims to enhance the assessment of treatment response, potentially leading to improved patient outcomes.
Harnessing AI to Advance Treatment Monitoring
PPF is characterised by progressive scarring of lung tissue, which leads to worsening respiratory function, diminished quality of life, and a poor prognosis.
While current oral antifibrotic treatments can slow disease progression, they often come with significant side effects that limit their long-term use. Avalyn’s AP01 offers an innovative inhaled formulation of pirfenidone, designed to reduce systemic exposure and enhance efficacy by delivering the medication directly to the lungs.
Qureight’s Core Imaging Platform will play a pivotal role in the MIST study by linking imaging data closely to clinical endpoints. Given the complex and often fragmented nature of PPF diagnosis and monitoring, this technology will provide a more refined and accurate measure of treatment response.
Furthermore, Qureight’s platform will extend its capabilities across multiple Avalyn clinical studies, reinforcing the potential of AI-driven imaging in pulmonary disease research.
Expert Insights on the Collaboration
The Chief Medical Officer of Avalyn Pharma highlighted the importance of this collaboration, stating that given the complex nature of PPF, they have made it a priority to leverage cutting-edge technology to measure treatment response in their ongoing MIST study.
Furthermore, they continued on to add that partnering with Qureight will allow them to measure changes in fibrosis volume more sensitively, which is essential for advancing new treatment options.
Similarly, the CEO of Qureight shared their excitement about the collaboration, expressing that as a lung disease doctor, they are thrilled about the future of inhaled therapies in treating progressive fibrotic lung diseases.
They continued on to emphasise that partnering with Avalyn on the MIST study presents an invaluable opportunity to see their Core Imaging Platform used to support PPF patients in a more precise and effective way.
Future Outlook: Advancing Medical Research with Data-Driven Insights
Both companies anticipate releasing further data analyses using Qureight’s technology at upcoming medical conferences.
This collaboration signals a significant step forward in pulmonary disease research, where artificial intelligence and deep-learning imaging can play a transformative role in understanding and treating complex conditions like PPF.
With no cure currently available for PPF, the integration of advanced imaging technologies into clinical trials offers new hope for patients and healthcare providers. By combining Avalyn’s targeted inhaled therapy with Qureight’s AI-powered imaging solutions, this partnership sets a new benchmark in precision medicine for fibrotic lung diseases.
As the research progresses, the potential for improved diagnostics, treatment monitoring, and patient outcomes continues to grow, paving the way for more effective and patient-friendly therapies in the future.
News Credits: Qureight and Avalyn launch strategic partnership in pulmonary fibrosis
Things you may also like:
- University of Nottingham and Murphy & Son Expand Brewing Partnership
- MHRA Grants Approval for Garadacimab to Prevent Angioedema Attacks
- Europe’s First Biomarker Trial to Prevent Crohn’s Disease